NEW YORK (GenomeWeb) – Systems Imagination (SII) announced today that it has partnered with Cofactor Genomics to offer services that combine their respective analytical research technologies and expertise for use in drug development.

Under the terms of the deal, the partners will join Cofactor's RNA-seq know-how with SII's big data analytics offerings. The resulting services, SII said, will help pharmaceutical research clients better understand and predict patient drug responses, identify disease targets, and develop combination therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.